´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 |
|
´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 ±³À°ÁÖÁ¦ : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ ´ã´çÀÚ : ÁÖÇýÁ¤ À̸ÞÀÏ : office@intervention.or.kr ±³À°Á¾·ù : ¿µ»óÀÇÇаú Âü¼®¿¹»óÀÎ : 300¸í Áö¿ª : ºÎ»ê±¤¿ª½Ã ¼¼ºÎ¼ö°·á : 120,000¿ø ºñ°í »çÀüµî·Ï-Á¤È¸¿ø50000¿ø, Àü¹®ÀÇ100000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 30000¿ø, ÁØȸ¿ø¹×±âŸ 50000¿ø/ÇöÀåµî·Ï-Á¤È¸¿ø70000¿ø, Àü¹®ÀÇ120000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 50000¿ø, ÁØȸ¿ø¹×±âŸ 70000¿ø
±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 12:50~13:00 Opening Remarks () ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:00~13:15 ´ëÇ÷°ü ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ÃÖÅ¿ø(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:15~13:30 º¹ºÎ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ¼»óÇö(¿ø±¤ÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:30~13:45 °ñ¹Ý/¿äµµ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ȲÁ¤ÇÑ(°¡ÃµÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:45~14:00 ¿Ü»ó¿Ü°úÀÇ°¡ ¹Ù¶óº» ÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐÀÇ ÇöȲ°ú ¿ªÇÒ ¹ÚÂù¿ë(¼¿ïÀÇ´ë) ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:00~14:20 Coffee break () ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:20~14:35 Current status of anticancer agents for cTACE in Korea ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:35~14:50 Idarubicin: an alternative to dox in cTACE ÃÖÁø¿ì(¼¿ïÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:50~15:05 Cisplatin-based cTACE ±èÁøÇü(¿ï»êÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:05~15:20 The role of DEB-TACE and bland embolization as alternative to cTACE À̺´Âù(Àü³²ÀÇ´ë) Åä·Ð 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:20~15:40 Panel discussion: Without Dox powder, what will be the approach for TACE? () ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:40~16:00 Coffee break () ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:00~16:20 Biliary stone removal using balloon catheter, stone basket ±è¼öÈ£, À±Á¾Çõ(°¡Å縯ÀÇ´ë, °í½ÅÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:20~16:40 GB stone removal technical tips, Biliary stone removal using ERCP and SpyGlass ±è¿µÈ¯, ÀÌ»óÈÆ(°è¸íÀÇ´ë, °Ç±¹ÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:40~17:00 Biliary stone: surgical consideration À¯Áø¼ö(¼º±Õ°üÀÇ´ë) ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:00~17:10 Coffee break () ±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:10~17:20 What¡¯s new () ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:20~14:32 (±¸¿¬¹ßÇ¥) Evaluation of patients undergoing Thoracic endovascular aortic repair for blunt thoracic aortic injury at a level 1 trauma center: Short term outcomes on left subclavian artery preservation with short proximal landing zones ±è¿ëÈÆ(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:32~14:44 (±¸¿¬¹ßÇ¥) Resorbable, Spherical Gelatin Particles versus Tris-Acryl Gelatin Microspheres for Uterine Artery Embolization: Randomized Controlled Trial ±è¸¸µæ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:44~14:56 (±¸¿¬¹ßÇ¥) The safety and efficacy of preoperative embolization in patients with bladder cancer, above T2 or VI-RADS 3 on CT and MRI: A Propensity Score-Matched Study ÀÌÈ£ÁØ(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:56~15:08 (±¸¿¬¹ßÇ¥) Clinical factors associated with femoral artery pseudoaneurysm after femoral access for interventional procedures ½Åº´±Ç(ÀüºÏÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 15:08~15:20 (±¸¿¬¹ßÇ¥) Ultrasound-Guided Femoral Branch Block for Femoral Arterial Access in Endovascular Aneurysm Repair: A Study on Analgesic Efficacy and Safety Á¶¿µÁ¾(¿ï»êÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:00~16:24 Diagnostic imaging of lymphatic disease: MR lymphangiography, CT lymphangiography Çã¼¼¹ü, ½ÅÁöÈÆ(¼¿ïÀÇ´ë, ¿ï»êÀÇ´ë) ±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:24~17:00 Treatment of chylothorax, traumatic chylous ascites, pelvic leaks and lymphoceles Çöµ¿È£, ±èÁø¿ì, ±è°æ¹Î(¼º±Õ°üÀÇ´ë, ¾ÆÁÖÀÇ´ë, ¿¬¼¼ÀÇ´ë)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|